About Us
About YD BioLabs
At YD BioLabs, we are at the forefront of the genomic revolution, harnessing the power of innovative, enzyme-driven Next-Generation DNA Synthesis (NGDS) technologies. Our proprietary platforms enable high-quality enzymatic DNA synthesis, rapid and precise nucleic acid labeling, and flexible modification techniques. These breakthroughs accelerate the DNA “design–build–test” innovation cycle, empowering medical research and advancing the future of molecular diagnostics and therapeutics.
Beyond synthesis, YD BioLabs supports cutting-edge applications such as rapid antibody-oligonucleotide conjugation, multiplexing nucleic acid-based probe production, and specialized enzyme tool development for DNA manipulation. Whether you’re pursuing discovery in basic research, healthcare industry, environmental protection, or molecular engineering, our solutions empower you to unlock the full potential of DNA and RNA applications.
Our mission: To transform possibilities in human health, environmental sustainability, and molecular innovation through world-leading nucleic acid technology. Let us help you shape the future at the molecular level.
Vision
Accelerating scientific innovation by revolutionizing nucleic acid synthesis, modification, and analysis with next-generation enzymatic technologies-streamlining complex workflows into powerful solutions for researchers worldwide.
Mission
We create and deliver cutting-edge, enzyme-powered tools for the DNA/RNA synthesis, labeling, and manipulation of nucleic acids. Our mission is to empower scientists and developers with faster, more precise, adaptable, and sustainable molecular solutions—enabling breakthroughs in research, diagnostics, therapeutics and beyond.
Our Story
Founded in 2019 in Hsinchu, Taiwan, YD BioLabs began its journey to advance the next-generation DNA synthesis and molecular tools by incorporating on March 19, 2019, and started operations at the NTHU Innovation & Incubation Hall later that year.
2020
YD BioLabs has rebranded, sharpening our focus on innovative enzyme-powered, next-generation nucleic acid synthesis technologies. Our proprietary enzyme-based DNA synthesis platform is driving advancements in the rapidly evolving field of genomics and synthetic biology, positioning YD BioLabs at the forefront of next-generation genetic solutions.
2021
The company secured seed funding from BIOLEGEND VENTURES, LLC, supporting the expansion of our research and development efforts, as well as drive growth in our business development.
2022
YD BioLabs recently showcased its innovative NGDS (Next-Generation DNA Synthesis) technology at the NTUCM Seminar. During the event, our team shared valuable insights into the latest developments in DNA synthesis, highlighting how our NGDS platform is shaping the future of genetic engineering and synthetic biology.
2023
Our enzyme-based DNA synthesis program received approval at the 2023 NSTC Park Review, underscoring our growing recognition and leadership in the field.
2024
YD BioLabs successfully relocated to the Hsinchu Biomedical Science Park, significantly enhancing our research, development, and production capabilities. In the same year, we launched our Rapid 5'-End ssDNA Labeling Kit, marking the introduction of our nucleic acid labeling product line. These milestones reflect our ongoing commitment to innovation and growth in the biotechnology sector.
2025
We have developed and implemented a state-of-the-art, in-house automated nucleic acid modification system. This advancement has significantly expanded our capacity for nucleic acid-based probe production, enhanced our Antibody–Oligonucleotide Conjugate (AOC) development capabilities, and streamlined our modular workflows.
Founder & CEO
Dr. Cheng-Yao Chen
Dr. Cheng-Yao Chen is the founder and CEO of YD BioLabs. With over two decades of experience in DNA sequencing and synthesis technologies, Dr. Chen is recognized as a leading innovator, holding more than 150 patents in the field. He earned his Ph.D. in Molecular & Cellular Biology from Oregon State University in Corvallis, Oregon, and has since built a distinguished international career spanning academia and industry.
Dr. Chen’s groundbreaking research and leadership in the development of sequencing-by-synthesis (SBS) technology were honored with the prestigious 2013 Illumina Innovation Award, recognizing his outstanding scientific contributions that were key to the commercial success of platforms such as MiSeq and HiSeq2500. Prior to founding YD BioLabs, Dr. Chen served as a staff scientist at Illumina, leading advanced research and development projects in DNA sequencing and gene synthesis.
Earlier in his career, Dr. Chen was a pivotal research scientist at Life Technologies (now part of ThermoFisher Scientific), driving the creation of third-generation, single-molecule DNA sequencing platforms. He also conducted postdoctoral research with Dr. Lawrence A. Loeb at the University of Washington, where his work focused on DNA replication and repair enzymes.
Dr. Chen’s expertise is reflected in his peer-reviewed publications, numerous patents, and his commitment to advancing molecular diagnostics and biotechnologies. His career demonstrates a dedication to scientific innovation and the translation of cutting-edge research into impactful commercial technologies.